To include your compound in the COVID-19 Resource Center, submit it here.

BeiGene starts Phase III of anti-PD-1 mAb in HCC

BeiGene Ltd. (NASDAQ:BGNE) said it began in December 2017 an open-label, international Phase III trial to compare tislelizumab (BGB-A317) to Nexavar sorafenib from

Read the full 230 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE